LumaCyte today announced that its analytical approach has been included in the newly published International Organization for Standardization (ISO) global standard for gene delivery systems, ISO 16921 ...

Next step in a broader collaboration to support VVMF build viral vector manufacturing capabilities Oxford, UK – 18 March 2026: OXB (LSE: OXB), a ...

Adeno-associated virus (AAV) vectors have become widely recognized as a fundamental tool in gene therapy, primarily due to their potential as a delivery system for the treatment of genetic disorders.

Mammoth Biosciences researchers have developed NanoCas, an ultracompact CRISPR nuclease, demonstrating its ability to perform gene editing in non-liver tissues, including skeletal muscle, using a ...

The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.

DUBLIN--(BUSINESS WIRE)--The "Adeno Associated Virus Vector Manufacturing Market Size, Share & Trends Analysis Report By Scale Of Operations (Clinical, Commercial), By Method, By Application, By ...

PHILADELPHIA--(BUSINESS WIRE)--VintaBio, a biotech manufacturer specializing in high-yield, high-purity viral vectors for gene therapy, today presented data further demonstrating the advantages and ...

The "Adeno-Associated Viral (AAV) Vector Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Therapy, Therapeutic Area, Route of Administration, Scale of Operation and ...

Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first commercial viral vector Contract Development and Manufacturing Organisation (CDMO), today announces that it has entered into a ...